Last year when we were hit with Covid-19, I sent out an email with my thoughts about the benefits of CBD, here is some of what I said:

CBD works a bit differently than THC on our endocannabinoid system.  CBD essentially asks our cells to release our cannabinoid molecules to enhance the immune and inflammatory system, by doing so, it decreases the release of the inflammatory cytokines and therefore causes an anti- inflammatory effect and it asks the immune system to work as well as it can to fight infections.  I recommend at least 50 mg per day of CBD. Here is a link to my video about CBD.”

 I was shared a very important article by one of our patients that was released from NIH and it confirms some of what I thought last year.  Here are some highlights of the article for you to view.  Again I cannot emphasize enough the benefits of daily doses of CBD.

Cannabidiol (CBD) Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response

L.C. Nguyễn, et.al.


Major points from the article:

  • CBD inhibits SARS-CoV-2 (Covid-19) infection
  • CBD blocks Covid-19 replication in lung epithelial cells  
  • CBD reverses many effects of Covid-19 on host gene transcription
  • Human patients previously taking CBD had significantly lower SARSCoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population
  • CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for Covid-19 at early stages of infection
  • The substantial reduction in Covid-19 infection risk of approximately an order of magnitude in patients who took FDA-approved CBD highlights the potential efficacy of this drug in combating Covid-19 infection
  • CBD may have efficacy against new pathogenic viruses arising in the future (like delta variant)
  • One mechanism of CBD is the induction of the interferon pathway which has been studied as a potential treatment for Covid-19
  • Importantly, CBD also suppresses cytokine activation in response to viral infection, reducing the likelihood of immune cell recruitment and subsequent cytokine storms within the lungs and other affected tissues. (See Dr. Hashim’s comments from last year)
  • CBD has the potential not only to act as an antiviral agent at early stages of infection but also to protect the host against an overactive immune system at later stages
  • CBD blocks viral replication after entry into cells and, thus, is likely to be effective against viral variants with mutant spike proteins
  • The purity of CBD and, in particular, the composition of the materials labelled as CBD are also important, especially in light of our findings suggesting that other cannabinoids such as THC might act to counter CBD antiviral efficacy
  • They would suggest moving to clinical trials rather than doing preclinical studies in animal models